Federal agencies found no evidence of system impact or nonpublic-data access; OpenAI has set no restart date.
The lab is not for clinical trials, and Claude-directed robotic experiments remain exploratory with human oversight.
Dario Amodei also wants slower capability gains, but shared standards still require other labs and governments to opt in.
The limited rollout starts with approved defenders, while coding agents and healthcare tools move into higher-stakes workflows.
OpenAI opens an experiment for agent-ready websites, while a London trial takes AI into brain surgery.
AWS adds cross-Region GPT-5.6 inference, while agent systems expose fresh operational limits.
